356 related articles for article (PubMed ID: 21050172)
1. GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics.
Atack JR
Curr Top Med Chem; 2011; 11(9):1176-202. PubMed ID: 21050172
[TBL] [Abstract][Full Text] [Related]
2. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement.
Atack JR
Curr Top Med Chem; 2011; 11(9):1203-14. PubMed ID: 21050171
[TBL] [Abstract][Full Text] [Related]
3. GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics.
Atack JR
Curr Top Behav Neurosci; 2010; 2():331-60. PubMed ID: 21309116
[TBL] [Abstract][Full Text] [Related]
4. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics.
Atack JR
Expert Opin Investig Drugs; 2005 May; 14(5):601-18. PubMed ID: 15926867
[TBL] [Abstract][Full Text] [Related]
5. Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site.
Atack JR
Curr Drug Targets CNS Neurol Disord; 2003 Aug; 2(4):213-32. PubMed ID: 12871032
[TBL] [Abstract][Full Text] [Related]
6. 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models.
Carling RW; Madin A; Guiblin A; Russell MG; Moore KW; Mitchinson A; Sohal B; Pike A; Cook SM; Ragan IC; McKernan RM; Quirk K; Ferris P; Marshall G; Thompson SA; Wafford KA; Dawson GR; Atack JR; Harrison T; Castro JL; Street LJ
J Med Chem; 2005 Nov; 48(23):7089-92. PubMed ID: 16279764
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist.
Atack JR; Hallett DJ; Tye S; Wafford KA; Ryan C; Sanabria-Bohórquez SM; Eng WS; Gibson RE; Burns HD; Dawson GR; Carling RW; Street LJ; Pike A; De Lepeleire I; Van Laere K; Bormans G; de Hoon JN; Van Hecken A; McKernan RM; Murphy MG; Hargreaves RJ
J Psychopharmacol; 2011 Mar; 25(3):329-44. PubMed ID: 20156926
[TBL] [Abstract][Full Text] [Related]
8. TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates.
Atack JR; Wafford KA; Tye SJ; Cook SM; Sohal B; Pike A; Sur C; Melillo D; Bristow L; Bromidge F; Ragan I; Kerby J; Street L; Carling R; Castro JL; Whiting P; Dawson GR; McKernan RM
J Pharmacol Exp Ther; 2006 Jan; 316(1):410-22. PubMed ID: 16183706
[TBL] [Abstract][Full Text] [Related]
9. MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans.
Atack JR; Wafford KA; Street LJ; Dawson GR; Tye S; Van Laere K; Bormans G; Sanabria-Bohórquez SM; De Lepeleire I; de Hoon JN; Van Hecken A; Burns HD; McKernan RM; Murphy MG; Hargreaves RJ
J Psychopharmacol; 2011 Mar; 25(3):314-28. PubMed ID: 20147571
[TBL] [Abstract][Full Text] [Related]
10. TP003 is a non-selective benzodiazepine site agonist that induces anxiolysis via α2GABA
Neumann E; Ralvenius WT; Acuña MA; Rudolph U; Zeilhofer HU
Neuropharmacology; 2018 Dec; 143():71-78. PubMed ID: 30240781
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of nonselective and subtype-selective gamma-aminobutyric acidA receptor positive modulators in the rat-conditioned emotional response test.
Mathiasen LS; Rodgers RJ; Mirza NR
Behav Pharmacol; 2007 May; 18(3):191-203. PubMed ID: 17426483
[TBL] [Abstract][Full Text] [Related]
12. Reinforcing effects of compounds lacking intrinsic efficacy at α1 subunit-containing GABAA receptor subtypes in midazolam- but not cocaine-experienced rhesus monkeys.
Shinday NM; Sawyer EK; Fischer BD; Platt DM; Licata SC; Atack JR; Dawson GR; Reynolds DS; Rowlett JK
Neuropsychopharmacology; 2013 May; 38(6):1006-14. PubMed ID: 23303046
[TBL] [Abstract][Full Text] [Related]
13. Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABA
Duke AN; Meng Z; Platt DM; Atack JR; Dawson GR; Reynolds DS; Tiruveedhula VVNPB; Li G; Stephen MR; Sieghart W; Cook JM; Rowlett JK
J Pharmacol Exp Ther; 2018 Jul; 366(1):145-157. PubMed ID: 29720564
[TBL] [Abstract][Full Text] [Related]
14. Discriminative stimulus effects of L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine): role of GABA(A) receptor subtypes.
Licata SC; Platt DM; Rüedi-Bettschen D; Atack JR; Dawson GR; Van Linn ML; Cook JM; Rowlett JK
Neuropharmacology; 2010 Feb; 58(2):357-64. PubMed ID: 19853619
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.
Atack JR; Maubach KA; Wafford KA; O'Connor D; Rodrigues AD; Evans DC; Tattersall FD; Chambers MS; MacLeod AM; Eng WS; Ryan C; Hostetler E; Sanabria SM; Gibson RE; Krause S; Burns HD; Hargreaves RJ; Agrawal NG; McKernan RM; Murphy MG; Gingrich K; Dawson GR; Musson DG; Petty KJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):470-84. PubMed ID: 19704033
[TBL] [Abstract][Full Text] [Related]
16. Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABA
Söderhielm PC; Balle T; Bak-Nyhus S; Zhang M; Hansen KM; Ahring PK; Jensen AA
Biochem Pharmacol; 2018 Dec; 158():339-358. PubMed ID: 30121248
[TBL] [Abstract][Full Text] [Related]
17. GABAA α5 subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the GABAA receptor allosteric modulator NS16085.
de Lucas AG; Ahring PK; Larsen JS; Rivera-Arconada I; Lopez-Garcia JA; Mirza NR; Munro G
Biochem Pharmacol; 2015 Feb; 93(3):370-9. PubMed ID: 25542996
[TBL] [Abstract][Full Text] [Related]
18. Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands.
Fradley RL; Guscott MR; Bull S; Hallett DJ; Goodacre SC; Wafford KA; Garrett EM; Newman RJ; O'Meara GF; Whiting PJ; Rosahl TW; Dawson GR; Reynolds DS; Atack JR
J Psychopharmacol; 2007 Jun; 21(4):384-91. PubMed ID: 17092983
[TBL] [Abstract][Full Text] [Related]
19. GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer.
Atack JR
CNS Neurosci Ther; 2008; 14(1):25-35. PubMed ID: 18482097
[TBL] [Abstract][Full Text] [Related]
20. A Pharmacogenetic 'Restriction-of-Function' Approach Reveals Evidence for Anxiolytic-Like Actions Mediated by α5-Containing GABAA Receptors in Mice.
Behlke LM; Foster RA; Liu J; Benke D; Benham RS; Nathanson AJ; Yee BK; Zeilhofer HU; Engin E; Rudolph U
Neuropsychopharmacology; 2016 Sep; 41(10):2492-501. PubMed ID: 27067130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
